Advertisement

Topics

Flex Pharma launches ALS phase 2 study with FLX-787 in US

04:58 EDT 2 Aug 2017 | Pharmaceutical Business Review

Flex Pharma has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial in the US.

Original Article: Flex Pharma launches ALS phase 2 study with FLX-787 in US

NEXT ARTICLE

More From BioPortfolio on "Flex Pharma launches ALS phase 2 study with FLX-787 in US"

Quick Search
Advertisement